Search Result

Results for "

EP2 receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Biochemical Assay Reagents (1) Endogenous Metabolite (5) Estrogen Receptor/ERR (1) Isotope-Labeled Compounds (1) PPAR (2) Prostaglandin Receptor (38) STAT (1) TGF-beta/Smad (1)
By Research Areas:	Cancer (7) Cardiovascular Disease (9) Endocrinology (22) Inflammation/Immunology (17) Metabolic Disease (2) Neurological Disease (2)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-153129

EP2 receptor antagonist-2	Prostaglandin Receptor	Endocrinology
EP2 receptor antagonist-2 (CID891729) is an antagonist of **EP2 receptor*. EP2* receptor antagonist-2 inhibits the EP2 receptor activation induced by PGE2. EP2 receptor antagonist-2 also suppresses lactate dehydrogenase (LDH) release induced by N-methyl-D-aspartate (NMDA) .

HY-145684

EP2 receptor antagonist-1	Prostaglandin Receptor	Inflammation/Immunology
EP2 receptor antagonist-1 (compound 1) is a potent, reversible, and agonist dependent allosteric prostaglandin EP2 receptor antagonist. EP2 receptor antagonist-1 shows anti-inflammatory effects .

HY-115462

PGN-9856	Prostaglandin Receptor	Inflammation/Immunology
PGN-9856 is a selective and high affinity (pK_i ≥ 8.3) ligand at **EP2 receptor*. PGN-9856 is a potetn and non-prostanoid EP2* receptor agonist (pEC₅₀ ≥ 8.5). PGN-9856 shows anti-inflammatory and anti-glaucoma activities .

HY-111406

Omidenepag isopropyl DE-117	Prostaglandin Receptor	Cardiovascular Disease Inflammation/Immunology
Omidenepag isopropyl is a selective EP2 receptor agonist. Omidenepag isopropyl is converted to the active product Omidenepag during corneal penetration, and Omidenepag is a highly selective EP2 receptor agonist. Omidenepag isopropyl shows only weak affinity for EP1, EP2, and FP receptors. Omidenepag isopropyl is under development for the treatment of glaucoma as an intraocular pressure (IOP)-lowering agent.

HY-14899

Taprenepag 4 Publications Verification CP-544326	Prostaglandin Receptor	Endocrinology
Taprenepag (CP-544326) is a potent and selective prostaglandin EP(2) agonist with IC₅₀s of 10 and 15 nM for human and rat EP2, respectively. Taprenepag shows selectivity for EP2 over other EP receptors (IC50s>3200 nM for EP1, EP3, and EP4) and a panel of 37 G protein-coupled receptors .

HY-19998

Taprenepag isopropyl 1 Publications Verification PF-04217329	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
Taprenepag isopropyl is a highly selective **EP₂ receptor** agonist.

HY-18971

TG4-155 1 Publications Verification	Prostaglandin Receptor	Neurological Disease Inflammation/Immunology Endocrinology Cancer
TG4-155 is a potent, brain-permeant and selective **EP2 receptor antagonist with a K_i** of 9.9 nM . TG4-155 shows low nanomolar antagonist activity against only EP2 and DP1 . TG4-155 has an EP2 Schild K_B of 2.4 nM and displays 550-4750-fold selectivity for EP2 over EP1, EP3, EP4 and IP, but only 14-fold selectivity against the DP1 receptor .

HY-10418

AH 6809 3 Publications Verification	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
AH 6809 is an antagonist of EP and DP receptor, with K_is of 1217, 1150, 1597, and 1415 nM for the cloned human EP₁, *EP₂, EP₃-III, and DP receptor* respectively. AH 6809 has a K_i of 350 nM for mouse EP₂ receptor .

HY-17642

Omidenepag 1 Publications Verification UR-7276	Prostaglandin Receptor	Endocrinology
Omidenepag (UR-7276), a pharmacologically active form of Omidenepag Isopropyl, is a selective, non-prostanoid *EP2* receptor agonist, with an EC₅₀ of 1.1 nM. Omidenepag shows binding affinities (IC₅₀) 10 nM for h-EP2 .

HY-121091

EP2 receptor agonist 4	Prostaglandin Receptor	Others
EP2 receptor agonist 4 is a selective agonist for EP2 receptor with an EC₅₀ of 43 nM .

HY-120973A

(S)-Butaprost free acid	Prostaglandin Receptor	Endocrinology
(S)-Butaprost (free acid) is a potent and highly selective agonist of *EP2* receptor .

HY-136696

11-Deoxy-16,16-dimethyl-PGE2	Prostaglandin Receptor	Metabolic Disease
11-Deoxy-16,16-dimethyl-PGE2, a Prostaglandin E2 analog, is a *EP2* and EP3 receptors agonist. 11-Deoxy-16,16-dimethyl-PGE2 protects proximal renal tubular epithelial cells from potent nephrotoxicity-induced cell damage by exerting anti-oxidative stress .

HY-16978

TG6-10-1 5+ Cited Publications	5-HT Receptor Prostaglandin Receptor	Neurological Disease Endocrinology
TG6-10-1 is an *EP2* antagonist, shows low-nanomolar antagonist activity against only EP2, >300-fold selectivity over human EP3, EP4, and IP receptors, 100-fold selectivity over EP1 receptors .

HY-100448A

Butaprost 2 Publications Verification	Prostaglandin Receptor TGF-beta/Smad	Endocrinology
Butaprost is a selective prostaglandin E receptor (EP2) agonist with an EC₅₀ of 33 nM and a K_i of 2.4 μM for murine EP2 receptor. Butaprost is less activity against murine EP1, EP3 and EP4 receptors. Butaprost attenuates fibrosis by hampering TGF-β/Smad2 signalling .

HY-139120

19(R)-hydroxy Prostaglandin E2 19(R)-Hydroxy PGE2; 19(R)-OH PGE2	Prostaglandin Receptor	Metabolic Disease
19(R)-hydroxy Prostaglandin E2 (19(R)-hydroxy PGE2) is found in the semen of primates, including man. It is a potent smooth muscle relaxant and a selective agonist for the EP2 receptor. It has an EC₅₀ value of 200 nM for relaxing cat tracheal rings which express EP2 receptors.

HY-18966

PF-04418948 5 Publications Verification	Prostaglandin Receptor	Endocrinology Cancer
PF-04418948 is an orally active, potent and selective prostaglandin EP₂ receptor antagonist with an IC₅₀ of 16 nM .

HY-18970

TG6-129	Prostaglandin Receptor	Inflammation/Immunology
TG6-129 is a selective antagonist of the **EP₂ receptor**. TG6-129 reduces the expression of inflammatory factors induced by butaprost in P388D1 macrophages .

HY-19864

Aganepag AGN 210937	Prostaglandin Receptor	Inflammation/Immunology
Aganepag is a potent Prostanoid EP2 receptor agonist, with an EC₅₀ of 0.19 nM, and shows no activity at EP4 receptor. Aganepag can be used in the research of wound healing, scar reduction, scar prevention and wrinkle treatment and prevention.

HY-14839A

Evatanepag sodium CP 533536	Prostaglandin Receptor	Cardiovascular Disease Inflammation/Immunology Endocrinology
Evatanepag sodium is a non-prostanoid, potent and selective **EP₂ receptor** agonist. Evatanepag sodium can induce local bone formation in vivo. Evatanepag sodium can be used in the research of fractures, bone defects, asthma .

HY-118609

*EP4 receptor* agonist 2**	Prostaglandin Receptor	Inflammation/Immunology
EP4 receptor agonist 2 (compound 31) a potent EP4 receptor agonist with an EC₅₀ value of 0.8 nM; K_i values of >100000, 38000, 3.1 nM for EP2, EP3, EP4 respectively .

HY-15274

L-798106 CM9; GW671021	Prostaglandin Receptor	Cancer
L-798106 is potent and highly selective prostanoid EP₃ receptor antagonist (K_i=0.3 nM), it also has ?micromolar activities at the EP₄, EP₁ and EP₂ receptors with K_i values of 916 nM, >5000 nM and >5000 nM, respectively .

HY-14839

Evatanepag 2 Publications Verification CP-533536 free acid	Prostaglandin Receptor	Cardiovascular Disease Inflammation/Immunology Endocrinology
Evatanepag (CP-533536) is a non-prostanoid, potent and selective **EP₂ receptor** agonist. Evatanepag can induce local bone formation in vivo. Evatanepag can be used in the research of fractures, bone defects, asthma .

HY-133123

*EP4 receptor* antagonist 1**	Prostaglandin Receptor	Inflammation/Immunology Cancer
EP4 receptor antagonist 1 is a highly potent and selective competitive prostanoid EP4 receptor antagonist for cancer immunotherapy. EP4 receptor antagonist 1 inhibits human and mouse EP4 receptor with IC₅₀s of 6.1 nM and 16.2 nM, respectively. IC₅₀s >10 μM for human EP1, EP2,and EP3 receptors .

HY-118190

AL 8810 methyl ester	Prostaglandin Receptor	Endocrinology
AL 8810 methyl ester is a prostaglandin F(2α) analog and a prostaglandin F(2α) receptor agonist. Can competitively antagonize the effects of the FP receptor agonist Fluprostenol (HY-108560). AL 8810 methyl ester has no significant potency against TP, DP, EP(2), EP(4) receptor subtypes in cell lines .

HY-N7748A

Epi-cryptoacetalide	Estrogen Receptor/ERR Prostaglandin Receptor	Inflammation/Immunology Endocrinology
Epi-cryptoacetalide is a natural diterpenoid. Epi-cryptoacetalide reveals high affinity to ER-α and *PGE2 receptor* (EP2 subtype) with K_i** values of 0.3 μM and 1.92 μM, respectively. Epi-cryptoacetalide has anti-endometriosis activities .

HY-B0131A

Alprostadil sodium	Prostaglandin Receptor	Cardiovascular Disease
Alprostadil sodium is a prostaglandin receptor ligand that exhibits Ki values of 36, 10, 1.1, 2.1, and 33 nM for the EP1, EP2, EP3, EP4, and IP receptors in mice, respectively. It promotes vasodilation and inhibits platelet aggregation, making it a useful vasodilator for investigating peripheral vascular disease.

HY-109163

Treprostinil palmitil INS-1009	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
Treprostinil palmitil (TP) is the proagent of DP1 and *EP2* agonist, Treprostinil (UT-15), whose EC₅₀ values were 0.6 and 6.2 nM, respectively. Treprostinil palmitil is a pure proagent and possesses no inherent binding to G-protein coupled receptors including prostanoid receptors .

HY-50848

BW A868C	Prostaglandin Receptor	Cardiovascular Disease
BW A868C, a hydantoin compound, is a BW245C structural analogue. BW A868C is a selective and potent competitive prostaglandin D2 (PGD2) antagonist. BW A868C has no effect on other prostaglandin receptors (IP, EP1, EP2, TP and FP) .

HY-114822

Prostaglandin A3 PGA3	Prostaglandin Receptor PPAR	Endocrinology
Prostaglandin A3 is a non-enzymatic dehydration product of prostaglandin E3 (PGE3). Prostaglandin A3 showed good affinity for canine EP2 and EP4 receptors with IC₅₀ values of 120 and 20 nM, respectively. The K_i value of Prostaglandin A3 for human PPARγ was 188 μM .

HY-164049

TG8-260	Prostaglandin Receptor	Inflammation/Immunology
TG8-260 is a second-generation *EP2* antagonist developed to alleviate the pathology of central nervous system and peripheral diseases driven by inflammation. TG8-260 can reduce neuroinflammation and gliosis in the hippocampus of rats after pilocarpine-induced persistent epileptic status. Pharmacokinetic data of TG8-260 showed that its plasma half-life was 2.14 hours and its oral bioavailability was 77.3%. TG8-260 is also a potent inhibitor of CYP450 and shows antagonistic activity in inhibiting *EP2* receptor-mediated inflammatory gene expression in BV2-hEP2 microglia, which is suitable for studying anti-inflammatory pathways in animal models of peripheral inflammatory diseases .

HY-10797

CJ-42794 1 Publications Verification CJ-042794	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
CJ-42794 (CJ-042794) is a potent, orally active, selective *prostaglandin E receptor* 4 (EP4) antagonist with an IC₅₀ value of 10 nM, which is 200-fold more selective than EP1, EP2 and EP3**. CJ-42794 can be used in research of gastric ulcers .

HY-128686

KAG-308 1 Publications Verification	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
KAG-308 is a potent selective and orally active agonist of EP4 receptor (a prostaglandin E2 receptor subtype), suppresses colitis and promotes histological mucosal healing, potently inhibits TNF-α production. KAG-308 shows a K_i and an EC₅₀ of 2.57 nM and 17 nM for human EP4 receptor, respectively, more selective over EP1, EP2, EP3 and IP receptor .

HY-115827

AH22921	Prostaglandin Receptor	Others
AH22921 is an EP4 prostaglandin receptor antagonist with the activity of antagonizing the activation of adenylate cyclase by prostaglandins in CHO cells. AH22921 can shift the PGE2 concentration-response curve to the right in CHO cells. It is a non-competitive antagonist that is selective for EP4 receptors and has an antagonistic effect on EP4 receptors in CHO cells, but does not affect the PGE2 concentration-response curve in NPE cells containing EP2 receptors.

HY-B0131

Prostaglandin E1 Maximum Cited Publications 11 Publications Verification Alprostadil; PGE1	Prostaglandin Receptor Endogenous Metabolite	Cardiovascular Disease Endocrinology Cancer
Prostaglandin E1 (Alprostadil) is a prostanoid receptor ligand, with K_is of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, *EP2, IP and EP1*, respectively. Prostaglandin E1 induces vasodilation and inhibits platelet aggregation. Prostaglandin E1 can be used as a vasodilator for the research of peripheral vascular diseases .

HY-B0131S2

Prostaglandin E1-d9 Alprostadil-d₉; PGE1-d₉	Isotope-Labeled Compounds Prostaglandin Receptor Endogenous Metabolite	Cardiovascular Disease Endocrinology
Prostaglandin E1-d₉ is deuterium labeled Prostaglandin E1.Prostaglandin E1 is a prostanoid receptor ligand, with Kis of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, EP2, IP and EP1, respectively. Prostaglandin E1 induces vasodilation and inh

HY-B0131S

Prostaglandin E1-d4	Prostaglandin Receptor Endogenous Metabolite	Cardiovascular Disease Endocrinology
Prostaglandin E1-d₄ is the deuterium labeled Prostaglandin E1. Prostaglandin E1 (Alprostadil) is a prostanoid receptor ligand, with Kis of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, EP2, IP and EP1, respectively. Prostaglandin E1 induces vasodilation and inhibits platelet aggregation. Prostaglandin E1 can be used as a vasodilator for the research of peripheral vascular diseases[1][2][3].

HY-B0131R

Prostaglandin E1 (Standard) Alprostadil(Standard); PGE1 (Standard)	Prostaglandin Receptor Endogenous Metabolite	Cardiovascular Disease Endocrinology Cancer
Prostaglandin E1 (Standard) is the analytical standard of Prostaglandin E1. This product is intended for research and analytical applications. Prostaglandin E1 (Alprostadil) is a prostanoid receptor ligand, with Kis of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, EP2, IP and EP1, respectively. Prostaglandin E1 induces vasodilation and inhibits platelet aggregation. Prostaglandin E1 can be used as a vasodilator for the research of peripheral vascular diseases .

HY-113205

15-keto-Prostaglandin E2 15-keto-PGE2	Endogenous Metabolite Prostaglandin Receptor STAT PPAR	Cancer
15-keto-Prostaglandin E2 is an endogenous metabolite. 15-keto-Prostaglandin E2 inhibits STAT3 activation by binding to its Cys259 residue. 15-keto-Prostaglandin E2 can bind and stabilize *EP2* and EP4 receptor. 15-keto-Prostaglandin E2 inhibits breast cancer cell growth and progression. 15-keto-Prostaglandin E2 activates PPAR-γ and promotes fungal growth .

HY-120973

Butaprost free acid	Biochemical Assay Reagents	Others
(R)-Butaprost (free acid). Butaprost is a structural analog of prostaglandin E2 (PGE2) with good selectivity for the EP2 receptor subtype. Butaprost is frequently used pharmacologically to define the expression profile of EP receptors in various human and animal tissues and cells. Gardiner caused serious confusion about the structure of butaprost in 1986 when he reported that the epimer of butaprost showing this selective activity was the C-16 (R)-epimer ( See reference 2 and notes). To increase the binding affinity of (R)-butaprost to prostaglandin receptors, we removed the methyl ester of (R)-butaprost and recreated the native C-1 carboxylic acid. Prostaglandin free acids typically bind their cognate receptors with 10 to 100-fold higher affinity than the corresponding ester derivatives. The pharmacology of (R)-butaprost has not been carefully studied, but it is generally considered to be the less active C-16 epimer. (Note: In the 1986 Gardiner paper in the British Journal of Pharmacology, butaprost appears on page 46 under the designation TR 4979. The structure drawn is incorrect because the authors use and refer to the more active C - The 16 epimer, which is actually 16(S). The structure on page 46 shows the structure as 16(R). It was not until the late 1990s that careful studies in the United States and Japan correctly determined the actual structure of C-16 The type is 16(S) in a compound called butaprost.)

Cat. No.	Product Name	Type

HY-120973

Butaprost free acid	Biochemical Assay Reagents
(R)-Butaprost (free acid). Butaprost is a structural analog of prostaglandin E2 (PGE2) with good selectivity for the EP2 receptor subtype. Butaprost is frequently used pharmacologically to define the expression profile of EP receptors in various human and animal tissues and cells. Gardiner caused serious confusion about the structure of butaprost in 1986 when he reported that the epimer of butaprost showing this selective activity was the C-16 (R)-epimer ( See reference 2 and notes). To increase the binding affinity of (R)-butaprost to prostaglandin receptors, we removed the methyl ester of (R)-butaprost and recreated the native C-1 carboxylic acid. Prostaglandin free acids typically bind their cognate receptors with 10 to 100-fold higher affinity than the corresponding ester derivatives. The pharmacology of (R)-butaprost has not been carefully studied, but it is generally considered to be the less active C-16 epimer. (Note: In the 1986 Gardiner paper in the British Journal of Pharmacology, butaprost appears on page 46 under the designation TR 4979. The structure drawn is incorrect because the authors use and refer to the more active C - The 16 epimer, which is actually 16(S). The structure on page 46 shows the structure as 16(R). It was not until the late 1990s that careful studies in the United States and Japan correctly determined the actual structure of C-16 The type is 16(S) in a compound called butaprost.)

Butaprost free acid

Biochemical Assay Reagents

(R)-Butaprost (free acid). Butaprost is a structural analog of prostaglandin E2 (PGE2) with good selectivity for the EP2 receptor subtype. Butaprost is frequently used pharmacologically to define the expression profile of EP receptors in various human and animal tissues and cells. Gardiner caused serious confusion about the structure of butaprost in 1986 when he reported that the epimer of butaprost showing this selective activity was the C-16 (R)-epimer ( See reference 2 and notes). To increase the binding affinity of (R)-butaprost to prostaglandin receptors, we removed the methyl ester of (R)-butaprost and recreated the native C-1 carboxylic acid. Prostaglandin free acids typically bind their cognate receptors with 10 to 100-fold higher affinity than the corresponding ester derivatives. The pharmacology of (R)-butaprost has not been carefully studied, but it is generally considered to be the less active C-16 epimer. (Note: In the 1986 Gardiner paper in the British Journal of Pharmacology, butaprost appears on page 46 under the designation TR 4979. The structure drawn is incorrect because the authors use and refer to the more active C - The 16 epimer, which is actually 16(S). The structure on page 46 shows the structure as 16(R). It was not until the late 1990s that careful studies in the United States and Japan correctly determined the actual structure of C-16 The type is 16(S) in a compound called butaprost.)

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0131

Prostaglandin E1 10+ Cited Publications Alprostadil; PGE1	Cardiovascular Disease Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields	Prostaglandin Receptor Endogenous Metabolite
Prostaglandin E1 (Alprostadil) is a prostanoid receptor ligand, with K_is of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, *EP2, IP and EP1*, respectively. Prostaglandin E1 induces vasodilation and inhibits platelet aggregation. Prostaglandin E1 can be used as a vasodilator for the research of peripheral vascular diseases .

HY-113205

15-keto-Prostaglandin E2 15-keto-PGE2	Structural Classification Ketones, Aldehydes, Acids Marine algae Marine natural products Source classification	Endogenous Metabolite Prostaglandin Receptor STAT PPAR
15-keto-Prostaglandin E2 is an endogenous metabolite. 15-keto-Prostaglandin E2 inhibits STAT3 activation by binding to its Cys259 residue. 15-keto-Prostaglandin E2 can bind and stabilize *EP2* and EP4 receptor. 15-keto-Prostaglandin E2 inhibits breast cancer cell growth and progression. 15-keto-Prostaglandin E2 activates PPAR-γ and promotes fungal growth .

HY-N7748A

Epi-cryptoacetalide	Terpenoids Labiatae Samanea saman (Jacq.) Merr. Diterpenoids Plants	Estrogen Receptor/ERR Prostaglandin Receptor
Epi-cryptoacetalide is a natural diterpenoid. Epi-cryptoacetalide reveals high affinity to ER-α and *PGE2 receptor* (EP2 subtype) with K_i** values of 0.3 μM and 1.92 μM, respectively. Epi-cryptoacetalide has anti-endometriosis activities .

HY-B0131R

Prostaglandin E1 (Standard) Alprostadil(Standard); PGE1 (Standard)	Cardiovascular Disease Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields	Prostaglandin Receptor Endogenous Metabolite
Prostaglandin E1 (Standard) is the analytical standard of Prostaglandin E1. This product is intended for research and analytical applications. Prostaglandin E1 (Alprostadil) is a prostanoid receptor ligand, with Kis of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, EP2, IP and EP1, respectively. Prostaglandin E1 induces vasodilation and inhibits platelet aggregation. Prostaglandin E1 can be used as a vasodilator for the research of peripheral vascular diseases .

Cat. No.	Product Name	Chemical Structure

HY-B0131S2

Prostaglandin E1-d9
Prostaglandin E1-d₉ is deuterium labeled Prostaglandin E1.Prostaglandin E1 is a prostanoid receptor ligand, with Kis of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, EP2, IP and EP1, respectively. Prostaglandin E1 induces vasodilation and inh

HY-B0131S

Prostaglandin E1-d4

Prostaglandin E1-d₄ is the deuterium labeled Prostaglandin E1. Prostaglandin E1 (Alprostadil) is a prostanoid receptor ligand, with Kis of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, EP2, IP and EP1, respectively. Prostaglandin E1 induces vasodilation and inhibits platelet aggregation. Prostaglandin E1 can be used as a vasodilator for the research of peripheral vascular diseases[1][2][3].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P83597

	*Prostaglandin E Receptor* EP2 Antibody (YA3342)** 1 Publications Verification EP2; PGE2 recEPtor EP2 subtype; Prostaglandin E recEPtor 2 subtype EP2 53kDa; Prostaglandin E2 recEPtor EP2 subtype; Prostanoid EP2 recEPtor; Ptger2	WB, IHC-P, ICC/IF, FC	Human, Mouse, Rat, Cow
	Prostaglandin E Receptor EP2 Antibody (YA3342) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3342), targeting Prostaglandin E Receptor EP2, with a predicted molecular weight of 40 kDa (observed band size: 52 kDa). Prostaglandin E Receptor EP2 Antibody (YA3342) can be used for WB, IHC-P, ICC/IF, FC experiment in human, mouse, rat, cow background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

EP2 receptor

Inhibitors & Agonists

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Antibodies

Natural
Products